Cancer research: from folate antagonism to molecular targets

Best Practice and Research: Clinical Haematology

Volumn 22, Issue 4, 2009, Pages 577-582

  Bertino, Joseph R ^a,b,c  

^a Stem Cell Institute of New Jersey ^*

^b Cancer Institute of New Jersey   (United States)

^c RUTGERS CANCER INSTITUTE OF NEW JERSEY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOPTERIN; ASPARAGINASE; CYCLOPHOSPHAMIDE; CYTARABINE; DIHYDROFOLATE REDUCTASE; DIHYDROFOLATE REDUCTASE INHIBITOR; FLUOROURACIL; FOLIC ACID; FOLIC ACID ANTAGONIST; FOLINIC ACID; GLUCARPIDASE; LENTIVIRUS VECTOR; LOMETREXOL; METHOTREXATE; PEMETREXED; PRALATREXATE; PREDNISONE; RALTITREXED; RETROVIRUS VECTOR; THYMIDYLATE SYNTHASE INHIBITOR; TRIMETREXATE; UNCLASSIFIED DRUG; VINCRISTINE; VIRUS VECTOR;

ACUTE LYMPHOCYTIC LEUKEMIA; CANCER RESEARCH; CANCER RESISTANCE; CELL PROTECTION; CHORIOCARCINOMA; CLINICAL TRIAL; COLON CANCER; DRUG MECHANISM; DRUG MEGADOSE; DRUG POTENCY; DRUG STRUCTURE; DRUG TARGETING; GENE AMPLIFICATION; GENE MUTATION; GENE TRANSFER; HEAD AND NECK CANCER; HEMATOPOIETIC CELL; HUMAN; LARGE CELL LYMPHOMA; LEUKEMIA REMISSION; LUNG ADENOCARCINOMA; MALIGNANT NEOPLASTIC DISEASE; MESOTHELIOMA; NONHUMAN; OSTEOSARCOMA; PRIORITY JOURNAL; REVIEW; SOLID TUMOR; TRANSLATION REGULATION;

AMINOPTERIN; FOLIC ACID ANTAGONISTS; HUMANS; METHOTREXATE; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; TETRAHYDROFOLATE DEHYDROGENASE; THYMIDYLATE SYNTHASE;

EID: 71749089415     PISSN: 15216926     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.beha.2009.09.004     Document Type: Review

References (29)

1. Osborn M.J., Freeman M., and Huennekens F.M. Inhibition of dihydrofolic reductase by aminopterin and amethopterin. Proc Soc Exp Biol Med 97 (1958) 429-431
2. O'Connor O.A., Horwitz S., Hamlin P., et al. Phase II-I-II Study of Two Different Doses and Schedules of Pralatrexate, a High-Affinity Substrate for the Reduced Folate Carrier, in Patients With Relapsed or Refractory Lymphoma Reveals Marked Activity in T-Cell Malignancies. J Clin Oncol (2009) Epub
3. Wang Y., Zhao R., and Goldman I.D. Characterization of a folate transporter in HeLa cells with a low pH optimum and high affinity for pemetrexed distinct from the reduced folate carrier. Clin Cancer Res 10 (2004) 6256-6264
4. Mitchell M.S., Wawro N.W., DeConti R.C., et al. Effectiveness of high-dose infusions of methotrexate followed by leucovorin in carcinoma of the head and neck. Cancer Res 28 (1968) 1088-1094
5. Berd D., Cornog J., DeConti R.C., et al. Long-term remission in diffuse histiocytic lymphoma treated with combination sequential chemotherapy. Cancer 35 (1975) 1050-1054
6. Bertino J.R., Sawicki W.L., Moroson B.A., et al. 2,4-diamino-5-methyl-6-[(3,4,5-trimethoxyanilino)methyl]quinazoline (tmq), a potent non-classical folate antagonist inhibitor-I effect on dihydrofolate reductase and growth of rodent tumors in vitro and in vivo. Biochem Pharmacol 28 (1979) 1983-1987
7. Allegra C.J., Kovacs J.A., Drake J.C., et al. Activity of antifolates against Pneumocystis carinii dihydrofolate reductase and identification of a potent new agent. J Exp Med 165 (1987) 926-931
8. Lacerda J.F., Goker E., Kheradpour A., et al. Selective treatment of SCID mice bearing methotrexate-transport-resistant human acute lymphoblastic leukemia tumors with trimetrexate and leucovorin protection. Blood 85 (1995) 2675-2679
9. Szelenyi H., Hohenberger P., Lochs H., et al. Sequential trimetrexate, 5-fluorouracil and folinic acid are effective and well tolerated in metastatic colorectal carcinoma. The phase II study group of the AIO. Oncology 58 (2000) 273-279
10. Punt C.J., van Maanen L., Bol C.J., et al. Phase I and pharmacokinetic study of the orally administered farnesyl transferase inhibitor R115777 in patients with advanced solid tumors. Anticancer Drugs 12 (2001) 193-197
11. Bertino J.R. Modulation of 5-fluorouracil/leucovorin by trimetrexate-did it work?. Ann Oncol 13 (2002) 10-11
12. Chabner B.A., Johns D.G., and Bertino J.R. Enzymatic cleavage of methotrexate provides a method for prevention of drug toxicity. Nature 239 (1972) 395-397
13. DeAngelis L.M., Tong W.P., Lin S., et al. Carboxypeptidase G2 rescue after high-dose methotrexate. J Clin Oncol 14 (1996) 2145-2149
14. Capizzi R.L. Asparaginase revisited. Suppl:. Leuk Lymphoma 10 (1993) 147-150
15. Alt F.W., Kellems R.E., Bertino J.R., et al. Selective multiplication of dihydrofolate reductase genes in methotrexate-resistant variants of cultured murine cells. J Biol Chem 253 (1978) 1357-1370
16. Gorlick R., Goker E., Trippett T., et al. Intrinsic and acquired resistance to methotrexate in acute leukemia. N Engl J Med 335 (1996) 1041-1048
17. Budak-Alpdogan T., and Bertino J.R. Chemoprotection by transfer of resistance genes. Methods Mol Biol 542 (2009) 661-704
18. Budak-Alpdogan T., Alpdogan O., Banerjee D., et al. Methotrexate and cytarabine inhibit progression of human lymphoma in NOD/SCID mice carrying a mutant dihydrofolate reductase and cytidine deaminase fusion gene. Mol Ther 10 (2004) 574-584
19. Cavazzana-Calvo M., Hacein-Bey S., de Saint B.G., et al. Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease. Science 288 (2000) 669-672
20. Noguchi P. Risks and benefits of gene therapy. N Engl J Med 348 (2003) 193-194
21. Deichmann A., Hacein-Bey-Abina S., Schmidt M., et al. Vector integration is nonrandom and clustered and influences the fate of lymphopoiesis in SCID-X1 gene therapy. J Clin Invest 117 (2007) 2225-2232
22. Aiuti A., Cassani B., Andolfi G., et al. Multilineage hematopoietic reconstitution without clonal selection in ADA-SCID patients treated with stem cell gene therapy. J Clin Invest 117 (2007) 2233-2240
23. Shou Y., Ma Z., Lu T., et al. Unique risk factors for insertional mutagenesis in a mouse model of XSCID gene therapy. Proc Natl Acad Sci U S A 103 (2006) 11730-11735
24. Ercikan-Abali E.A., Banerjee D., Waltham M.C., et al. Dihydrofolate reductase protein inhibits its own translation by binding to dihydrofolate reductase mRNA sequences within the coding region. Biochemistry 36 (1997) 12317-12322
25. Chu E., Takimoto C.H., Voeller D., et al. Specific binding of human dihydrofolate reductase protein to dihydrofolate reductase messenger RNA in vitro. Biochemistry 32 (1993) 4756-4760
26. Guo W., Healey J.H., Meyers P.A., et al. Mechanisms of methotrexate resistance in osteosarcoma. Clin Cancer Res 5 (1999) 621-627
27. Goto Y., Yue L., Yokoi A., et al. A novel single-nucleotide polymorphism in the 3'-untranslated region of the human dihydrofolate reductase gene with enhanced expression. Clin Cancer Res 7 (2001) 1952-1956
28. Mishra P.J., Humeniuk R., Mishra P.J., et al. A miR-24 microRNA binding-site polymorphism in dihydrofolate reductase gene leads to methotrexate resistance. Proc Natl Acad Sci U S A 104 (2007) 13513-13518
29. Song B., Wang Y., Kudo K., et al. miR-192 Regulates dihydrofolate reductase and cellular proliferation through the p53-microRNA circuit. Clin Cancer Res 14 (2008) 8080-8086